FDA, CMS To Begin Collaborating On Drug Safety Data Collection In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS Medical Innovation Task Force report says CMS will assist FDA in postmarketing drug surveillance. The collaboration also includes parallel reviews by the two agencies to minimize delays between marketing approval and reimbursement.
You may also be interested in...
E-Clinical Trials Standardization Is Goal Of Trans-HHS Tech Innovation Push
The standardization initiative is outlined by a task force consisting of NIH, CDC, FDA and CMS chiefs. The group also directs HHS to educate department officials in technology transfer policies – a project the task force believes can be accomplished in a “matter of months.”
E-Clinical Trials Standardization Is Goal Of Trans-HHS Tech Innovation Push
The standardization initiative is outlined by a task force consisting of NIH, CDC, FDA and CMS chiefs. The group also directs HHS to educate department officials in technology transfer policies – a project the task force believes can be accomplished in a “matter of months.”
CBER Pilot Seeks To Improve Use Of Electronic Datasets
Sponsors are asked to volunteer to evaluate tools used to analyze nonclincial and clinical electronic datasets. FDA expects to recommend detailed standards for the submission of animal and human data.